



Docket No.: 022290.0159PTUS
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Gauthier Pouliquen et al.

Application No.: 10/580,023

Confirmation No.: 7549

Filed: May 19, 2006

Art Unit: 1654

For: PHARMACEUTICAL FORMULATIONS
FOR THE PROLONGED RELEASE OF
ACTIVE PRINCIPLE(S) AND THEIR
THERAPEUTIC APPLICATIONS

Examiner: S. Gudibande

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Similarly, copies of Office Actions issued in commonly-owned U.S. patent applications directed to similar subject matter, also stored and available to the Examiner in electronic form in the Office's IFW system, have not been submitted. 69 FR 56481, 56510, Sept. 21, 2004. In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h),


the filing of this Supplemental Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Supplemental Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Applicants believe no fee is due with this Supplemental Information Disclosure Statement. If a fee is due, however, the Director is authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed for this application (or with any paper filed in this application by this firm) to our Deposit Account No. 50-2228, under Order No. 022290.0159PTUS.

Dated: September 25, 2009

Respectfully submitted,

By 
Lacy L. Kolo
Registration No.: 55,340
PATTON BOGGS LLP
8484 Westpark Drive, 9th Floor
McLean, Virginia 22102
(703) 744-8029
(703) 744-8001 (Fax)
Attorney for Applicants